Canada’s biomedical brain drain is reversing. Let’s continue that trend

We must look beyond the lab and build a thriving ecosystem to make sure Canadian biomedical treatments are developed here and benefit Canadians.

To shepherd breakthroughs, we need a framework that allows stakeholders to share research, development, manufacturing, and entrepreneurial expertise, write Michael May and Allison Brown. Photograph courtesy of the National Cancer Institute

Opinion

BY MICHAEL MAY, ALLISON BROWN

January 8, 2024

Every Canadian family has been touched by cancer, heart disease, diabetes, or Alzheimer’s disease. Facing these diseases as a patient or a loved one will become a grim reality for even more families as the baby boom generation ages.

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Tuesdays: Innovation & Industry Newsletter

The policies, decisions, and people working on investment and regulation in the industry and innovation realm.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy